Susanna Waters

4PUBLICATIONS
3CO-AUTHORS
Clinical pharmacology and therapeuticsBiologically active moleculesToxicology (incl. clinical toxicology)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Feb 26, 2025
Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial.

Angelo Antonini, Padraig O'Suilleabhain, Fabricio Stocchi

|Jul 02, 2020
(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent.

S Hjorth, S Waters, N Waters

|May 03, 2020
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease.

Susanna Waters, Clas Sonesson, Peder Svensson

|Dec 21, 2016
In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery.

Susanna Waters, Peder Svensson, Johan Kullingsjö

Pageof 1

Frequent Collaborators

1 joint publications

Peder Svensson

1 joint publications

Padraig O'Suilleabhain

1 joint publications

Fabricio Stocchi